GNRH1 and prostate carcinoma: Both GnRH-I agonists and antagonists are able to inhibit the growth of cancer cells in sex hormone-regulated tissues including ovarian cancer and prostate cancer, by directly stimulating cell death pathways as well as by decreasing gonadotropin and sex hormone levels [11], [32], [33].